Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Daniel Petrylak shares interim results from Duravelo-2, a study of zelenectide in patients with one prior line of therapy for metastatic urothelial carcinoma. Zelenectide is a bicyclic peptide ...

Yijun Shen discusses phase two results from a single-arm study of SHR-A2102 plus adebrelimab as neoadjuvant therapy in muscle-invasive bladder cancer. SHR-A2102 is a nectin-4 antibody-drug conjugate ...

Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...

Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...

Juan Ruiz-Bañobre presents an ultrasensitive ctDNA analysis in advanced clear cell RCC, using a tumor-informed whole genome sequencing assay on serial plasma samples from 37 treatment-naive patients ...

Ronald Chen presents quality of life results from the AMBASSADOR trial, a randomized study of adjuvant pembrolizumab versus observation in high-risk urothelial carcinoma after radical surgery. Quality ...

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...

The management of metastatic hormone-sensitive prostate cancer (mHSPC) has rapidly evolved into a complex landscape of doublet and triplet combination strategies. While treatment intensification was ...

The study aimed to evaluate whether continuing α-blocker therapy for one month after aquablation improves early clinical outcomes in patients undergoing surgery for benign prostatic obstruction (BPO).

Over the past decades, both hypofractionation and (focal) dose escalation have been studied in trials for prostate cancer (PCa) radiotherapy. Several studies have demonstrated a benefit of dose ...

To evaluate the financial impact of surgical modalities for benign prostatic hyperplasia (BPH) from the perspective of an NHS Trust. A retrospective analysis of patients undergoing Aquablation, ...